|
|
Post by sellhighdrinklow on Oct 11, 2017 14:37:07 GMT -5
Are we to assume that the results of this study will not be disclosed until the next American Diabetes Association annual meeting, scheduled for Orlando Florida,
June 22-28. 2018? I really hope this is not the case.
|
|
|
|
Post by liane on Oct 11, 2017 18:28:13 GMT -5
I had originally locked this thread because of the "assumption". But enough people have expressed interest in weighing in. So it is now unlocked.
|
|
|
|
Post by dreamboatcruise on Oct 11, 2017 18:50:18 GMT -5
Are we to assume that the results of this study will not be disclosed until the next American Diabetes Association annual meeting, scheduled for Orlando Florida, June 22-28. 2018? I really hope this is not the case. Before I make assumptions about what you meant, can you clarify why you've worded your question making it seem you believe disclosure will be held until ADA? |
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Oct 11, 2017 18:54:41 GMT -5
Are we to assume that the results of this study will not be disclosed until the next American Diabetes Association annual meeting, scheduled for Orlando Florida, June 22-28. 2018? I really hope this is not the case. Before I make assumptions about what you meant, can you clarify why you've worded your question making it seem you believe disclosure will be held until ADA? I assume he is being sarcastic. |
|
|
|
Post by cjc04 on Oct 11, 2017 19:03:13 GMT -5
I'm interested in understanding this too,,, its kinda a big deal...
Somewhere today, in some thread, I read a post that someone quoted Mike from one of the recent investor presentations. I believe it was his list of what's next and he said they'd get the results later in the 4th quarter and they'd present them sometime next year...,
True or not, whatever, I don't know,,,, maybe someone has the transcript..
Sry, that's all I got.
|
|
|
|
Post by dreamboatcruise on Oct 11, 2017 19:10:00 GMT -5
I'm interested in understanding this too,,, its kinda a big deal... Somewhere today, in some thread, I read a post that someone quoted Mike from one of the recent investor presentations. I believe it was his list of what's next and he said they'd get the results later in the 4th quarter and they'd present them sometime next year..., True or not, whatever, I don't know,,,, maybe someone has the transcript.. Sry, that's all I got. Yes, he did say next year. It does take some time to crunch numbers after the clinical portion of a study is concluded so perhaps that was all that was meant, but now thinking about his statement it does seem oddly definitive as if there is some particular date in 2018 rather than simply being as soon as the data crunching is done. I too hope they don't hold it. Even if they do, I'm sure it would be very valuable in discussions with international partners, which I'm sure they could do. I wonder if it would be useful for sales rep discussions with doctors if being held for ADA. |
|
|
|
Post by sayhey24 on Oct 11, 2017 19:17:12 GMT -5
Are we to assume that the results of this study will not be disclosed until the next American Diabetes Association annual meeting, scheduled for Orlando Florida, June 22-28. 2018? I really hope this is not the case. Now that's a good question. In the old days the answer would probably be yes when the ADA was the BIG show. Last years ADA was a BIG mess and the ADA even tried to stop presenters from sending presentation and studies out via social media. ADA 2018 will be more of an IT show displaying phone apps, monitoring services and Cloud Diabetes. Nothing will be announced which is better than Tresiba and nothing is in anyone's pipeline that can touch afrezza. The question with the study is can it be leveraged into a new protocol? Assuming nothing comes close to afrezza, is releasing the study early to influence an Edelman/Ondou protocol for example, prior to ADA 2018 have more value than presenting it at the ADA. IMO, the ADA ain't what it use to be. If afrezza becomes the center piece of these real time monitoring services by leveraging the STAT results, I think you will see it sooner than later. |
|
|
|
Post by sellhighdrinklow on Oct 11, 2017 20:36:23 GMT -5
Are we to assume that the results of this study will not be disclosed until the next American Diabetes Association annual meeting, scheduled for Orlando Florida, June 22-28. 2018? I really hope this is not the case. Before I make assumptions about what you meant, can you clarify why you've worded your question making it seem you believe disclosure will be held until ADA? Was not the recent label change based on data presented to ADA in June, 2016 that was based on data originally collected in late 2015? AND, it was delayed, to be presented to ADA in June 2016, because ADA wouldn't present it unless it was new info? ...AND Mannkind waited to present so as to amplify the importance? If I'm incorrect, please correct me. |
|
|
|
Post by sellhighdrinklow on Oct 11, 2017 21:05:45 GMT -5
Castagna stated that the data from the STAT study would be reported in 2018.
The numbers wouldn't need to be crunched from this study. The data is/would be straight forward.
Maybe Sayhey can explain why 2018's ADA will be different. He seems to be quite dialed in.
|
|
|
|
Post by sellhighdrinklow on Oct 11, 2017 21:11:59 GMT -5
Castagna stated that the data from the STAT study would be reported in 2018. The numbers wouldn't need to be crunched from this study. The data is/would be straight forward. Maybe Sayhey can explain why 2018's ADA will be different. He seems to be quite dialed in. Never mind. He already answered. Results sooner than later. I hope so. |
|
|
|
Post by ghochr on Oct 11, 2017 21:19:20 GMT -5
ADA requires the data not be released if a company needs to present data as breakthrough in ADA to gain attention . It depends. Study results take time to analyze and get the report and Mannkind can choose what they want to do.
|
|
|
|
Post by sellhighdrinklow on Oct 11, 2017 21:49:55 GMT -5
In May, MNKD stock ran up to $1.90+ after announcement of the STAT study to be started mid June. There was a one day delay before folks figured it out. (Sunday to Tuesday) The STAT study is a 99% positive conclusion for Mannkind as I mentioned in a previous thread. My opinion of course but based on 40 years as a Type 1 and 29 months as an Afrezza user! ! !
The 10 million shares sold at $6 is no coincidence as the STAT study is coming to a conclusion. The facts/results of the STAT study were conclusive weeks ago (again, imho). Do you think those 10 million Shares would have been sold at $6 after a 300% run up in such a short time without the STAT evidence presented? No chance.
When the STAT study data is presented, it's off to the races again for MNKD share price and the Adam Fs of the world can watch and weep.
No brainer.
|
|
|
|
Post by zumiker on Oct 12, 2017 3:30:36 GMT -5
If the results were imminent and so positive, wouldn't it be prudent to wait to do the offering until after they announced the results??
|
|
|
|
Post by InvesterSam on Oct 12, 2017 4:23:59 GMT -5
If the results were imminent and so positive, wouldn't it be prudent to wait to do the offering until after they announced the results?? I trust Mike's and his team's decision. They may not have time to wait any longer, considering the current cash balance. There are so many possibly good PRs lined up in short time period. I feel great. |
|
|
|
Post by mnholdem on Oct 12, 2017 4:32:26 GMT -5
Official Title: Study Comparing Prandial Insulin Aspart vs. Technosphere Insulin in Patients With Type 1 Diabetes on Multiple Daily Injections: Investigator-Initiated A Real-life Pilot Study—STAT Study
clinicaltrials.gov/ct2/show/NCT03143816?term=STAT&cond=Diabetes&draw=1&rank=1
If the primary/secondary endpoint results show superiority against using insulin aspart (Novolog) alone for significantly reducing/controlling post-prandial glucose excursions (PPGE) and reduction of HbA1c, wouldn't you much rather see the results published in Lancet than at the ADA Scientific Meetings? Publishing in a major medical journal would educate far more doctors about the merits of Afrezza than an ADA presentation would, IMO.
There may be further label ramifications from this University of Colorado study as well... 
|
|
